GlassScriptPhysician profile
James Timothy Kim
NPI 1649698481
$5,939.92
in general payments reported to CMS, 2019-2025
22 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $703 · 2021: $1,255 · 2022: $2,204 · 2023: $1,268 · 2024: $323 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,789.16 | 2020-2022 | |
| Medtronic, INC. | $1,128.44 | 2022-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Kyphon Express II Kyphopak Tray |
| Nalu Medical, INC. | $1,075.09 | 2020-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $1,007.36 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Stimwave Technologies Incorporated | $124.04 | 2020 | |
| Stryker Corporation | $119.74 | 2020 | |
| Medtronic USA, INC. | $79.16 | 2020 | |
| Grt US Holding, INC. | $78.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.04 | 2020-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $59.33 | 2022-2023 | Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $56.89 | 2022 | |
| Redhill Biopharma INC. | $53.86 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $48.18 | 2021-2024 | Ztlido |
| Curonix LLC | $43.06 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceuticals, INC. | $42.49 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $34.11 | 2020-2023 | Genvisc 850 Sodium Hyaluronate |
| Abbvie INC. | $31.79 | 2024 | |
| Spinal Simplicity, LLC | $25.14 | 2025 | Ha Minuteman G3-R |
| Forte Bio-Pharma LLC | $18.93 | 2023 | Prolate, Nalocet |
| Azurity Pharmaceuticals, INC. | $17.61 | 2024 | Horizant |
| Biotronik Nro, INC. | $14.68 | 2024 | Prospera |
| Arbor Pharmaceuticals, INC. | $14.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.